LTS Lohmann Therapie Systeme (LTS) is the market leader in transdermal therapeutic systems (TTS) and oral thin film (OTF).

The company develops and manufactures innovative drug delivery systems that offer reliable therapeutic efficacy, with convenience and comfort.

Transdermal therapeutic systems (TTS) and microneedle research

In addition to the further development of TTS and oral thin film (OTF) technologies, the company actively researches microneedle systems, as well as other TTS technologies such as iontophoresis.

As a B2B partner to the pharmaceutical industry, LTS offers solutions at all stages of product development, including feasibility assessments, research and development of new formulations, production of clinical, as well as commercial scale supplies, and primary and secondary packaging.

LTS has a large expertise in the development of innovative drug delivery systems that specialise in the transdermal application of existing and novel agents.

Based on successful feasibility assessments, LTS is a preferred partner for pharmaceutical industries for the development and manufacture of transdermal therapeutic systems.

The company’s expertise, as well as numerous technology tools, assures a high probability for a successful development.

Patches and oral thin films as pharmaceutical dosage forms

LTS produces patches and oral thin films in large quantities for the global market. A comprehensive service is offered, that includes packaging development and support in the product approval process.

LTS also offers contract manufacturing services for existing formulations and products.

Pharmaceutical companies can take advantages of more than 30 years of experience from the market leader for transdermal systems.

High volume patch manufacturing

The company has sufficient capacity to manufacture high-volume products. LTS production facilities in Germany and the US both provide identical equipment for product manufacturing. LTS can offer its customers secure supply chain reliability, even during crisis periods.

LTS is recognised by major health authorities worldwide.

Separate production of hormone and non-hormone products

The company systematically separates production of hormone products from non-hormone products, in order to avoid any risk of possible cross-contamination.

LTS supports every customer with its very own development committee, which allows participation of customers’ research teams during development work.

LTS covers all relevant technical steps in product development, from feasibility studies up to the market launch, and subsequent large-scale manufacturing.